AnaptysBio shares sag as Sanofi-Regeneron trial stokes IL-33 doubts

A 12% dip in AnaptysBio's share price Friday suggests investors are concerned that a Phase II readout for a rival IL-33 inhibitor could indicate that the drug class may not provide a differentiated clinical benefit in asthma compared with marketed drug Dupixent.

Sanofi (Euronext:SAN; NASDAQ:SNY) and

Read the full 459 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE